Chronic wounds & diabetic foot ulcers

What changes during this transition

Chronic non-healing wounds are a high-stakes, protocol-heavy clinical space where the standard-of-care toolkit drives outcomes by orders of magnitude more than any peptide adjunct. The major drivers are well-characterized: diabetic foot ulcers (DFU) affect 15–25% of T2D patients lifetime and account for roughly 60% of nontraumatic lower-extremity amputations; venous stasis ulcers (VSU) are the most common LE ulcer overall and require compression therapy as foundation; pressure ulcers depend on immobility + tissue tolerance, with turning protocols, support surfaces, and nutrition as the primary levers; arterial and mixed-etiology ulcers require revascularization workup before any healing intervention is meaningful. The intervention ladder for DFU specifically is now tightly defined and outranks any peptide consideration in effect size: glycemic control (A1C individualized, time-in-range >70%, ADA position statement), off-loading (total-contact cast is the Tier 1 intervention per IWGDF), serial sharp debridement, moisture balance, IDSA 2023 infection management guidelines, revascularization workup if pulses are diminished or ABI is abnormal, and HBO therapy in select cases (TIME trial 2017 was negative for DFU but the modality is still used in non-healing radiation-injury and ischemic-wound contexts). The adjunct tier above standard-of-care is also defined: cellular and tissue-based products (Apligraf, Dermagraft, Grafix, Affinity), becaplermin (Regranex, recombinant PDGF gel — FDA-approved for DFU), negative-pressure wound therapy (NPWT / VAC), and the EU-approved UrgoStart sucrose-octasulfate dressing. The multi-jurisdictional context worth surfacing: Cuba's Heberprot-P (recombinant human EGF) is not FDA-approved but is registered for DFU in roughly 25 countries and has Phase 3 data in its source jurisdictions — it is not in the Juno library but it is the multi-jurisdictional editorial backdrop against which the US 'no FDA-approved peptide for DFU' framing should be read. US FDA approval is not the world authority on peptide therapeutics, and the wound-care space is one where that distinction matters. The library's strongest peptide-adjacent cases on this axis are the three primary-research-domain anchors plus the endogenous antimicrobial: BPC-157 (Sikiric group, Zagreb — 30+ years rodent wound-healing across skin, vascular, anastomotic, ischemic-flap; zero human DFU RCT), TB-500 / thymosin β-4 (Goldstein lab — primary research domain is wound healing; RGN-259 Phase 3 program for neurotrophic keratitis the furthest clinical translation; Phase 2 work in pressure ulcers, VSU, and EB stalled short of approval), GHK-Cu (Pickart 40+ years copper-peptide wound research; Mulder 1994 small pressure-ulcer signal; no DFU Phase 3; complicated by huge OTC cosmetic-market noise), and LL-37 (endogenous antimicrobial with documented defective expression in diabetic skin per Rivas-Santiago 2008 / Gonzalez-Curiel 2014; Carretero 2008 wound-healing acceleration in murine models; small Asian-population DFU trials without Phase 3 progression; HARD autoimmune contraindication thread for psoriasis / lupus / MS / Th17-IFN-I-driven conditions where LL-37 is the operative disease mechanism). Semaglutide is surfaced as a PREVENTION substrate — glycemic control + weight loss reduce DFU risk via reduced neuropathy progression, microvascular disease, and plantar pressure, but the framing is prevention via metabolic control, not direct wound treatment, and there is no direct DFU-prevention trial as primary endpoint. What's NOT surfaced is editorially load-bearing. CJC-1295 / ipamorelin / tesamorelin / IGF-1 LR3 GH-axis peptides have plausible biology for tissue repair but their evidence base is body composition / GH-axis insufficiency, not chronic wounds; no chronic-wound trial. Cerebrolysin and semax are neurotrophic and don't extend to skin wound healing. Thymosin alpha-1 immune-modulation isn't aligned with chronic-wound pathophysiology. The four peptides surfaced are the ones with actual chronic-wound primary research or endogenous physiological role.